JP2017531693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531693A5 JP2017531693A5 JP2017538177A JP2017538177A JP2017531693A5 JP 2017531693 A5 JP2017531693 A5 JP 2017531693A5 JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017531693 A5 JP2017531693 A5 JP 2017531693A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- population
- epicensus
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 297
- 102000036639 antigens Human genes 0.000 claims description 297
- 108091007433 antigens Proteins 0.000 claims description 297
- 229960005486 vaccine Drugs 0.000 claims description 185
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 86
- 241000701022 Cytomegalovirus Species 0.000 claims description 36
- 230000004927 fusion Effects 0.000 claims description 28
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 23
- 108090000565 Capsid Proteins Proteins 0.000 claims description 18
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 18
- 229940033332 HIV-1 vaccine Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 101710177291 Gag polyprotein Proteins 0.000 claims description 12
- 101710125418 Major capsid protein Proteins 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 12
- 239000000969 carrier Substances 0.000 claims description 9
- 101710186352 Probable membrane antigen 3 Proteins 0.000 claims description 7
- 101710181078 Probable membrane antigen 75 Proteins 0.000 claims description 7
- 101710178472 Tegument protein Proteins 0.000 claims description 7
- 101150088910 UL82 gene Proteins 0.000 claims description 7
- 241000710929 Alphavirus Species 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 241000711408 Murine respirovirus Species 0.000 claims description 6
- 241000710799 Rubella virus Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 241000560067 HIV-1 group M Species 0.000 claims description 4
- 230000007498 myristoylation Effects 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 230000005867 T cell response Effects 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 3
- 238000010187 selection method Methods 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059497P | 2014-10-03 | 2014-10-03 | |
| US201462059506P | 2014-10-03 | 2014-10-03 | |
| US62/059,506 | 2014-10-03 | ||
| US62/059,497 | 2014-10-03 | ||
| PCT/US2015/054067 WO2016054654A1 (en) | 2014-10-03 | 2015-10-05 | Hiv vaccines comprising one or more population episensus antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170852A Division JP7212020B2 (ja) | 2014-10-03 | 2020-10-09 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017531693A JP2017531693A (ja) | 2017-10-26 |
| JP2017531693A5 true JP2017531693A5 (enExample) | 2018-11-15 |
Family
ID=55631703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538177A Pending JP2017531693A (ja) | 2014-10-03 | 2015-10-05 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
| JP2020170852A Active JP7212020B2 (ja) | 2014-10-03 | 2020-10-09 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
| JP2023003194A Active JP7441340B2 (ja) | 2014-10-03 | 2023-01-12 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170852A Active JP7212020B2 (ja) | 2014-10-03 | 2020-10-09 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
| JP2023003194A Active JP7441340B2 (ja) | 2014-10-03 | 2023-01-12 | １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10894078B2 (enExample) |
| EP (1) | EP3200878B1 (enExample) |
| JP (3) | JP2017531693A (enExample) |
| KR (1) | KR102633096B1 (enExample) |
| CN (1) | CN108064181A (enExample) |
| AU (2) | AU2015327797A1 (enExample) |
| CA (1) | CA2963573C (enExample) |
| EA (1) | EA201790680A1 (enExample) |
| HK (1) | HK1254806A1 (enExample) |
| IL (1) | IL251469B2 (enExample) |
| MA (1) | MA40783A (enExample) |
| MX (3) | MX391149B (enExample) |
| SG (1) | SG11201702729YA (enExample) |
| UA (1) | UA126890C2 (enExample) |
| WO (1) | WO2016054654A1 (enExample) |
| ZA (1) | ZA202206809B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| JP6890831B2 (ja) | 2015-07-08 | 2021-06-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖ予備免疫化および免疫療法 |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| WO2018009246A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| WO2020243485A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| PH12022550490A1 (en) | 2019-08-29 | 2023-02-06 | Triad Nat Security Llc | Hepatitis b virus vaccines |
| JP7693813B2 (ja) | 2021-01-14 | 2025-06-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン及び使用方法 |
| US20240384296A1 (en) | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| TW202436326A (zh) * | 2023-02-13 | 2024-09-16 | 長怡 王 | 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者 |
| CN116524994A (zh) * | 2023-02-20 | 2023-08-01 | 中国科学院天津工业生物技术研究所 | 一种基于贪婪算法的菌株构建排程设计方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| BR0212619A (pt) | 2001-09-20 | 2004-08-17 | Glaxo Group Ltd | Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo |
| AUPR842501A0 (en) * | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| EP1609107A4 (en) * | 2003-03-28 | 2006-08-30 | Idm Pharma Inc | METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS |
| CN1852734B (zh) | 2003-09-17 | 2010-12-01 | 杜克大学 | 共有/祖先免疫原 |
| AU2011203095A1 (en) | 2003-09-17 | 2011-07-21 | Duke University | Consensus/Ancestral Immunogens |
| NZ547042A (en) | 2003-10-10 | 2010-05-28 | Powderject Vaccines Inc | Method for eliciting a T-cell response |
| EP1766096B1 (en) | 2004-05-25 | 2013-01-02 | Oregon Health and Science University | Hiv vaccination usingand hcmv-based vaccine vectors |
| WO2007024941A2 (en) * | 2005-08-23 | 2007-03-01 | The Regents Of The University Of California | Polyvalent vaccine |
| KR102511874B1 (ko) | 2006-07-28 | 2023-03-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
| US20110123485A1 (en) * | 2007-03-27 | 2011-05-26 | President And Fellows Of Harvard College | Viral vectors for delivering vaccines for hiv and other infectious diseases |
| US20100183651A1 (en) * | 2007-03-30 | 2010-07-22 | Finnefrock Adam C | Broadly Representative Antigen Sequences and Method for Selection |
| SMT201800631T1 (it) | 2008-11-18 | 2019-01-11 | Beth Israel Deaconess Medical Ct Inc | Vaccini antivirali con immunogenicità cellulare migliorata |
| KR20120093941A (ko) * | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성 |
| EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| WO2011143653A2 (en) | 2010-05-14 | 2011-11-17 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
| US8557787B2 (en) | 2011-05-13 | 2013-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| ES2718899T3 (es) | 2012-03-02 | 2019-07-05 | Us Gov Health & Human Services | Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas |
| EP2983686B1 (en) * | 2013-01-07 | 2024-05-29 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| PL2964769T3 (pl) * | 2013-03-05 | 2019-03-29 | Oregon Health & Science University | Wektory cytomegalowirusa umożliwiające kontrolę ukierunkowania limfocytów T |
| CA2941116A1 (en) | 2014-02-28 | 2015-09-03 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| AU2015289560B2 (en) | 2014-07-16 | 2018-09-27 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| EA202092521A1 (ru) | 2014-09-26 | 2021-05-31 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| TWI792091B (zh) | 2015-12-15 | 2023-02-11 | 荷蘭商傑森疫苗防護公司 | 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法 |
-
2015
- 2015-10-04 MA MA040783A patent/MA40783A/fr unknown
- 2015-10-05 US US15/516,491 patent/US10894078B2/en active Active
- 2015-10-05 CA CA2963573A patent/CA2963573C/en active Active
- 2015-10-05 MX MX2017004275A patent/MX391149B/es unknown
- 2015-10-05 IL IL251469A patent/IL251469B2/en unknown
- 2015-10-05 SG SG11201702729YA patent/SG11201702729YA/en unknown
- 2015-10-05 KR KR1020177012171A patent/KR102633096B1/ko active Active
- 2015-10-05 HK HK18113892.2A patent/HK1254806A1/zh unknown
- 2015-10-05 EA EA201790680A patent/EA201790680A1/ru unknown
- 2015-10-05 UA UAA201704021A patent/UA126890C2/uk unknown
- 2015-10-05 JP JP2017538177A patent/JP2017531693A/ja active Pending
- 2015-10-05 CN CN201580063643.3A patent/CN108064181A/zh active Pending
- 2015-10-05 EP EP15847978.2A patent/EP3200878B1/en active Active
- 2015-10-05 WO PCT/US2015/054067 patent/WO2016054654A1/en not_active Ceased
- 2015-10-05 AU AU2015327797A patent/AU2015327797A1/en not_active Abandoned
-
2017
- 2017-03-31 MX MX2022003663A patent/MX2022003663A/es unknown
- 2017-03-31 MX MX2022003664A patent/MX2022003664A/es unknown
-
2020
- 2020-08-31 US US17/008,289 patent/US11628215B2/en active Active
- 2020-08-31 US US17/008,335 patent/US11554168B2/en active Active
- 2020-10-09 JP JP2020170852A patent/JP7212020B2/ja active Active
-
2021
- 2021-08-19 AU AU2021218141A patent/AU2021218141B2/en active Active
-
2022
- 2022-06-20 ZA ZA2022/06809A patent/ZA202206809B/en unknown
-
2023
- 2023-01-12 JP JP2023003194A patent/JP7441340B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531693A5 (enExample) | ||
| Doria-Rose et al. | Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge | |
| CA2949851C (en) | Htert sequences and methods for using the same | |
| Lu | Heterologous prime–boost vaccination | |
| Hanke | Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines | |
| Ross et al. | Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference | |
| Earl et al. | Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate | |
| Karpenko et al. | Novel approaches in polyepitope T-cell vaccine development against HIV-1 | |
| Knudsen et al. | Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen | |
| Latanova et al. | Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity | |
| Larijani et al. | HIV-1 p24-nef DNA vaccine plus protein boost expands T-cell responses in BALB/c | |
| Ajbani et al. | Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and polRT genes | |
| Sundbäck et al. | Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles | |
| Liu et al. | The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice | |
| Shephard et al. | A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice | |
| van Harmelen et al. | Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa | |
| Anderson et al. | Overcoming original (antigenic) sin | |
| Menon et al. | DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant | |
| Blomquist et al. | Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide | |
| Anraku et al. | Kunjin replicon-based simian immunodeficiency virus gag vaccines | |
| Dereuddre-Bosquet et al. | HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations | |
| Klein | Prospects and challenges for prophylactic and therapeutic HIV vaccines | |
| Clutton et al. | Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines | |
| Stenler et al. | Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses | |
| Mayr et al. | Antibodies targeting the envelope of HIV‐1 |